A 32 Biomarker Assay for Advanced Breast Cancer
Using our novel Reverse Phase Protein Arrays (RPPA), we can measure the activation state of key drug targets and signaling pathways within a microscopic quantity of tumor sample. By measuring the drug targets themselves in this way, we are able to go beyond genetics and genomics to aid in treatment decision making.
What we offer
Ease of Ordering
Our ordering process consists of a one-page test request form to be completed by the treating physician's office, with key information required - location of the sample, treatment history, pathology report and relevant insurance information. Once received, our team will do the rest
How to Order
Actionable Results
All 32 biomarkers on the assay are tied to FDA approved drugs, so a result with significant findings will show which drugs are most appropriate based on the expression and activation of that target.
Sample report
Clinical Support
Our team of expert scientists and researchers bring a wealth of knowledge and experience to Ignite Proteomics. As specialists in the field of proteomic, our team is committed to providing the extra level of support needed to better understand the role that proteomics can have in developing your treatment plan.
Contact our teamTreatment options for breast cancer continue to grow. We can help navigate your choices.
With continued excitement around the approval of antibody drug conjugates like trastuzumab deruxtecan, being able to measure the drug target itself has never been more important. To learn how we measure key biomarkers like total HER2 and phospho-HER2, along with the 30 other key biomarkers in the breast cancer treatment pathway, please clink the link below.
Contact usWatch: Ignite Proteomics in 3 Minutes
3-minute explainer video
In preparation